Characteristics of Subcutaneous Injectable Products as Presented to Study Participants

Existing 3-Month Product4-Month Product Concept6-Month Product Concept
Amount of medroxyprogesterone acetate104 mg104 mg150 mg
Reinjection window4 weeks1 weekNot specified
Ability to self-injectYesYesNo
Return to fertilityNot describedPotentially shorter than existing 3-monthNot specified
Side effectsNot describedPotentially fewer than existing 3-monthSimilar to existing 3-month
Regulatory approval/ state of evidenceApprovedStudies demonstrate effectiveness for 4-monthsEffectiveness trial is ongoing